Ai‐Ming Yu
YOU?
Author Swipe
View article: Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions
Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions Open
Small RNA or oligonucleotide therapeutics represent a unique modality outside the traditional treatment paradigm of small molecule and protein-based drugs that have historically only targeted a small fraction of the proteome. Innovations i…
View article: Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor
Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor Open
View article: Practical Pharmacokinetic–Pharmacodynamic Models in Oncology
Practical Pharmacokinetic–Pharmacodynamic Models in Oncology Open
Integrated pharmacokinetic (PK) and pharmacodynamic (PD) models are essential for the understanding of quantitative relationship between drug exposure and response towards the identification of optimal dosing regimens in drug development a…
View article: A reference-guided iterative approach to polish the nanopore sequencing basecalling for therapeutic RNA quality control
A reference-guided iterative approach to polish the nanopore sequencing basecalling for therapeutic RNA quality control Open
Nucleotide modifications deviate nanopore sequencing readouts, therefore generating artifacts during the basecalling of sequence backbones. Here, we present a reference-guided, iterative approach to polish modification-disturbed basecallin…
View article: Anterior bone loss after anterior cervical discectomy and fusion: influence factors and its impact on surgical outcomes
Anterior bone loss after anterior cervical discectomy and fusion: influence factors and its impact on surgical outcomes Open
View article: Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study
Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study Open
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality. Emerging evidence suggests that quadruple therapy – combining hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TA…
View article: Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary figure
View article: Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
Supplementary data
View article: Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
Supplementary data
View article: Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary figure
View article: Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors Open
View article: The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage
The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage Open
The Non-coding Journal Editorial Board Members would like to congratulate Victor Ambros and Gary Ruvkun, who were jointly awarded the 2024 Nobel Prize in Physiology or Medicine for their groundbreaking discovery of microRNAs and the role o…
View article: Multi-omics insights into beagle dog fed with a sucking-rewarded automatic feeding device
Multi-omics insights into beagle dog fed with a sucking-rewarded automatic feeding device Open
Background Facilitating the development of the sucking function in early stages of preterm infants holds substantial potential for influencing their long-term outcomes. To this end, our team has devised a sucking-rewarded automatic feeding…
View article: Figure 4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure 4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
PINK1 expression is increased in 2B-OlapR cells and associated with negative patient prognosis. Treating 2B-OlapR cells with siPINK1 ASOs decreases PINK1 expression and protein level, as well as cell growth, and improves olaparib efficacy.…
View article: Figure 3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure 3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
Mitochondrial live stain and ETC functional test demonstrate higher function in 2B-OlapR cells. A, Left, MitoTracker staining counterstained with nuclear-specific DAPI reveals higher amounts of relative mitochondrial mass in 2B-Olap…
View article: Figure 2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure 2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
Seahorse Mito Stress Test assay results comparing C4-2B and 2B-OlapR cells at basal state and with mitochondrial inhibitor supplementation to deduce relative function. A and B, Mito Stress Test summary graphic representing di…
View article: Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary figure
View article: Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Figure 5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure 5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
Seahorse Mito Stress Test assay results comparing 2B-OlapR cells with and without siPINK treatment at basal state and with mitochondrially relevant pharmacologic supplementation to deduce relative function convey decreased function after P…
View article: Figure 6 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure 6 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
Inhibiting PINK1 expression decreases relative active mitochondria and lowers ETCC1 activity. A, Left, 2B-OlapR cells treated with siPINK1 show lower relative positive MitoTracker staining. 10× images shown, with 20× crops within. R…
View article: Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Data from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Data from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
Olaparib, a PARP inhibitor, is a targeted therapy used in treating various cancers, including castration-resistant prostate cancer. Despite its efficacy, resistance to olaparib remains a significant challenge. Understanding the molecular m…
View article: Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
supplementary data
View article: Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open
Supplementary data